Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsTrendsHealthZydus gets DCGI nod for emergency use of 'Virafin' in treating moderate COVID-19 cases

    Zydus gets DCGI nod for emergency use of 'Virafin' in treating moderate COVID-19 cases

    The company has claimed that 91.15 percent of COVID-19 patients treated with Virafin were RT-PCR negative by day 7.

    Moneycontrol News
    April 23, 2021 / 15:49 IST
    Representative image

    Pharmaceutical firm Zydus Cadila received emergency use approval from the Drug Controller General of India (DCGI) - country's apex medicine regulator - on April 23 for the use of 'Virafin' in treating moderate COVID-19 cases.

    Virafin, technically referred to as Pegylated Interferon alpha-2b, showed clinical and virological improvement in moderate COVID-19 cases, the company said, as per the CNBC-TV18 report.

    Zydus has claimed that "91.15% of patients treated with PegIFN were RT-PCR negative by day 7", the report added.

    The treatment significantly "reduces the hours of supplemental oxygen in the patients", the company was further reported as saying..

    The reduction in usage of supplemental oxygen, as claimed by Zydus, could come as a relief to states who are struggling in the COVID-19 fight due to the stressed supply of medicine oxygen.

    COVID-19 Vaccine

    Frequently Asked Questions

    View more
    How does a vaccine work?

    A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

    How many types of vaccines are there?

    There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

    What does it take to develop a vaccine of this kind?

    Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

    View more
    Show

    Related stories

    Several states across the country have raised alarm, with Delhi Chief Minister Arvind Kejriwal warning of catastrophic consequences if the oxygen supply is not stabilised at the earliest.

    "We fear a big tragedy may happen due to oxygen shortage and we will never be able to forgive ourselves. I request you with folded hands to direct all CMs to ensure smooth movement of oxygen tankers coming to Delhi," he said during the meeting," Kejriwal said during the meeting of chief ministers with Prime Minister Narendra Modi on April 23.

    Apart from medicine oxygen, a number of states have also claimed shortage of Remdesivir - the antiviral drug administered to some of the hospitalised COVID-19 patients.

    Also read: Zydus Cadila’s Covid-19 vaccine: How it compares with peers, manufacturing capacities and challenges, explained

    The emergency use approval of Virafin also comes amid a severe COVID-19 second wave in India, with an unprecedented surge seen in per-day count of infections. The country, as per the last update issued on April 23, reported 3.32 lakh new cases and 2,263 more deaths.

    Moneycontrol News
    first published: Apr 23, 2021 03:17 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347